1
|
Abstract
Objectives Tamoxifen (TAM), which is used for treating breast cancer, has exhibited another important function as an antimicrobial agent. The objective of this study is to investigate the antibacterial action of TAM against the bacteria present in the human oral cavity. Materials and Methods The bacteria present in the human oral cavity were isolated from healthy individuals. Different concentrations of TAM were tested against the isolated bacteria. Additionally, bactericidal and bacteriostatic effects of TAM were also determined. Results Out of 23 isolated bacteria, a greater number of Gram-positive bacteria were highly susceptible to the low concentrations of TAM than Gram-negative bacteria. Kytococcus sedentarius, which is Gram-positive bacterium, and Pseudomonas stutzeri, which is Gram-negative bacterium, needed a high minimum inhibitory concentration value of TAM (2.5 mg/mL) to be inhibited by TAM's bacteriostatic action. Resistance to TAM was also observed in three strains of Gram-positive and four strains of Gram-negative bacteria. Conclusion TAM has shown a potential antibacterial effect against the bacteria present in the oral cavity, especially against Gram-positive bacteria. This effect is mostly bacteriostatic. This study also found bacterial resistance toward TAM.
Collapse
|
2
|
Abdmouleh F, El Arbi M, Saad HB, Jellali K, Ketata E, Amara IB, Pigeon P, Hassen HB, Top S, Jaouen G, Hammami R, Ali MB, Gupta GK. Antimicrobial, Antitumor and Side Effects Assessment of a Newly Synthesized Tamoxifen Analog. Curr Top Med Chem 2020; 20:2281-2288. [PMID: 32814527 DOI: 10.2174/1568026620666200819145526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 07/20/2020] [Accepted: 07/20/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Tamoxifen citrate is a very prevalent drug marketed under several trade names like Apo-Tamox, Nolvadex, Tamec, Tamizam, and Tamoplex. This molecule is approved by the FDA for breast cancer treatment. Some studies have shown that tamoxifen has anti-tuberculosis and antiparasitic activities. Like any drug, tamoxifen possesses side effects, more or less dangerous. AIMS Basically, this work is a comparative study that aims to: primarily compare the antimicrobial and antitumor activities of tamoxifen and a newly synthesized tamoxifen analog; and to determine the molecule with lesser side effects. METHODS Three groups of mice were injected with tamoxifen citrate and compound 2(1,1-bis[4-(3- dimethylaminopropoxy)phenyl]-2-phenyl-but-1-ene dihydrochloride) at doses corresponding to C1 (1/10), C2 (1/50), and C3 (1/100) to compound 2 lethal dose (LD50 = 75 mg/kg) administered to adult mice. A group of noninjected mice served as a study control. RESULTS Experimental results suggest that compound 2 has better antitumor and antimicrobial activity than tamoxifen citrate besides its lower toxicity effects. CONCLUSION The results obtained from the present study confirmed the antitumor and antimicrobial effect of tamoxifen citrate and its hematological side effects. Compound 2 seems to be more effective than tamoxifen citrate for antitumor and antimicrobial treatment while having less hematological side effects and less disruption of the blood biochemical parameters. These findings encourage us to perform further studies on compound 2 and test it for other therapeutic uses for which tamoxifen was found effective.
Collapse
Affiliation(s)
- Fatma Abdmouleh
- Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia
| | - Mehdi El Arbi
- Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia,Higher Institute of Biotechnology of Sfax, University of Sfax, Route de Sokra km 4, 3000 Sfax, Tunisia
| | - Hajer Ben Saad
- Faculty of Medicine, University of Sfax, Laboratory of Pharmacology UR/12 ES-13, 3029 Sfax, Tunisia
| | - Karim Jellali
- Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia
| | - Emna Ketata
- Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia
| | - Ibtissem Ben Amara
- Higher Institute of Biotechnology of Sfax, University of Sfax, Route de Sokra km 4, 3000 Sfax, Tunisia
| | - Pascal Pigeon
- Sorbonne Université, UMR 8232 CNRS, IPCM, 4 place Jussieu, F-75005 Paris, France,PSL, Chimie ParisTech, 11 rue Pierre et Marie Curie, F-75005 Paris (France)
| | - Hanen Ben Hassen
- Higher Institute of Biotechnology of Sfax, University of Sfax, Route de Sokra km 4, 3000 Sfax, Tunisia
| | - Siden Top
- Sorbonne Université, UMR 8232 CNRS, IPCM, 4 place Jussieu, F-75005 Paris, France
| | - Gérard Jaouen
- Sorbonne Université, UMR 8232 CNRS, IPCM, 4 place Jussieu, F-75005 Paris, France,PSL, Chimie ParisTech, 11 rue Pierre et Marie Curie, F-75005 Paris (France)
| | - Riadh Hammami
- School of Nutrition Sciences, University of Ottawa, Ottawa, K1N 7 K4, ON, Canada
| | - Mamdouh Ben Ali
- Centre of Biotechnology of Sfax, University of Sfax, Route de Sidi Mansour km 6, 3018 Sfax, Tunisia
| | - Girish Kumar Gupta
- Departemt of Pharmaceutical Chemistry, Sri Sai College of Pharmacy, Badhani, Pathankot-145001, Punjab, India
| |
Collapse
|
3
|
Garg A, Singh B, Sharma R, Singh A, Kumar A. Selective Estrogen Receptor Modulators (SERMs): Mechanistic Insights Against Microbial Infections. Curr Mol Med 2020; 20:102-115. [PMID: 31622201 DOI: 10.2174/1566524019666191014112133] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Revised: 09/06/2019] [Accepted: 09/13/2019] [Indexed: 12/31/2022]
Abstract
Background:
Infections are one of the leading causes of death worldwide
and currently available treatments remain unsatisfactory due to rise in the cases of
antimicrobial resistance. Thus, there is a need for the development of new drugs with
different mechanisms of action. However, the development of new antimicrobials agents
is a long and expensive process. Hence, most of the pharmaceutical companies are
Methodology:
The data related to SERMs and microbial infection has been extracted
from Pub Med (from January 1997 to December 2018). A total of 101 studies have been
published from 1997 -2018 regarding SERMs and microbial infections.
Results:
On the basis of inclusion and exclusion criteria, 25 studies have been included
for the analysis of level of evidence regarding antimicrobial effects of SERMs. Emerging
reports have indicated the antimicrobial property of selective estrogen receptor
modulators (SERMs) against normal and resistant strains under in vitro and in vivo
conditions against wide variety of microorganisms through different mechanisms of
action.
Conclusion:
In conclusion, SERMs could be developed as a broad spectrum
antimicrobial agent alone or in combination with existing antimicrobial agents.
Collapse
Affiliation(s)
- Aakriti Garg
- Department of Pharmacology, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India
| | - Balraj Singh
- Department of Pharmacology, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India
| | - Ruchika Sharma
- Department of Biotechnology, Indo-Soviet Friendship Institute of Professional Studies (ISFIPS), Moga, Punjab, India
| | - Arti Singh
- Department of Pharmacology, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India
| | - Anoop Kumar
- Department of Pharmacology, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, Punjab, India
| |
Collapse
|
4
|
The inhibition of tyrosinase by some aryl butenes: A desired activity or a side effect to avoid. J Organomet Chem 2017. [DOI: 10.1016/j.jorganchem.2017.07.031] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Hussein MH, Schneider EK, Elliott AG, Han M, Reyes-Ortega F, Morris F, Blaskovich MAT, Jasim R, Currie B, Mayo M, Baker M, Cooper MA, Li J, Velkov T. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative “Superbugs” Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Microb Drug Resist 2017; 23:640-650. [DOI: 10.1089/mdr.2016.0196] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Maytham H. Hussein
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Elena K. Schneider
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Alysha G. Elliott
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
| | - Meiling Han
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Felisa Reyes-Ortega
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Faye Morris
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Mark A. T. Blaskovich
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
| | - Raad Jasim
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Bart Currie
- Menzies School of Health Research, Casuarina, Australia
| | - Mark Mayo
- Menzies School of Health Research, Casuarina, Australia
| | - Mark Baker
- Priority Research Centre in Reproductive Science, School of Environmental and Life Sciences, University of Newcastle, Callaghan, Australia
| | - Matthew A. Cooper
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
| | - Jian Li
- Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Parkville, Australia
| | - Tony Velkov
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| |
Collapse
|
6
|
Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative 'superbugs'. Essays Biochem 2017; 61:115-125. [PMID: 28258235 DOI: 10.1042/ebc20160058] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 11/02/2016] [Accepted: 11/03/2016] [Indexed: 12/13/2022]
Abstract
The emergence of antimicrobial resistance of Gram-negative pathogens has become a worldwide crisis. The status quo for combating resistance is to employ synergistic combinations of antibiotics. Faced with this fast-approaching post-antibiotic era, it is critical that we devise strategies to prolong and maximize the clinical efficacy of existing antibiotics. Unfortunately, reports of extremely drug-resistant (XDR) Gram-negative pathogens have become more common. Combining antibiotics such as polymyxin B or the broad-spectrum tetracycline and minocycline with various FDA-approved non-antibiotic drugs have emerged as a novel combination strategy against otherwise untreatable XDR pathogens. This review surveys the available literature on the potential benefits of employing antibiotic-non-antibiotic drug combination therapy. The apex of this review highlights the clinical utility of this novel therapeutic strategy for combating infections caused by 'superbugs'.
Collapse
|
7
|
Hanchi H, Hammami R, Fernandez B, Kourda R, Ben Hamida J, Fliss I. Simultaneous Production of Formylated and Nonformylated Enterocins L50A and L50B as well as 61A, a New Glycosylated Durancin, by Enterococcus durans 61A, a Strain Isolated from Artisanal Fermented Milk in Tunisia. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2016; 64:3584-3590. [PMID: 27111259 DOI: 10.1021/acs.jafc.6b00700] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Enterococcus durans 61A, a broad-spectrum strain, was isolated from artisanal fermented dairy products. The strain is a multibacteriocin producer, free from virulence genes, and could be considered a good candidate for application in food preservation. In the present study, E. durans 61A was shown to produce simultaneously formylated and nonformylated forms of leaderless enterocins L50A and L50B as well as 61A, a new glycosylated durancin. Bacteriocins were characterized using mass spectrometry. Formylation was found to increase enterocin antimicrobial activity of enterocin L50A (8×) and, to a lesser extent, the activity of L50B (2×). Durancin 61A was found glycosylated by two hexoses (glucose and arabinose) and exhibited broad-spectrum inhibition against Gram-positive and Gram-negative bacteria and fungal spores. Durancin 61A was highly bactericidal at 15.6 μg/mL (10× the MIC) on Listeria innocua HPB13 and seems to target bacterial membrane as shown by ion efflux and transmission electron microscopy.
Collapse
Affiliation(s)
- Hasna Hanchi
- STELA Dairy Research Centre, Institute of Nutrition and Functional Foods, Université Laval , Québec, QC, Canada G1K 7P4
- Unité de Protéomie Fonctionnelle & Biopréservation Alimentaire, Institut Supérieur des Sciences Biologiques Appliquées de Tunis, Université Tunis El Manar , Tunis, Tunisia
| | - Riadh Hammami
- STELA Dairy Research Centre, Institute of Nutrition and Functional Foods, Université Laval , Québec, QC, Canada G1K 7P4
| | - Benoit Fernandez
- STELA Dairy Research Centre, Institute of Nutrition and Functional Foods, Université Laval , Québec, QC, Canada G1K 7P4
| | - Rim Kourda
- Unité de Protéomie Fonctionnelle & Biopréservation Alimentaire, Institut Supérieur des Sciences Biologiques Appliquées de Tunis, Université Tunis El Manar , Tunis, Tunisia
| | - Jeannette Ben Hamida
- Unité de Protéomie Fonctionnelle & Biopréservation Alimentaire, Institut Supérieur des Sciences Biologiques Appliquées de Tunis, Université Tunis El Manar , Tunis, Tunisia
| | - Ismail Fliss
- STELA Dairy Research Centre, Institute of Nutrition and Functional Foods, Université Laval , Québec, QC, Canada G1K 7P4
| |
Collapse
|
8
|
El Arbi M, Jalléli K, Trigui F, Pigeon P, Görmen M, Top S, Aifa S, Fliss I, Jaouen G, Hammami R. Efficacy of a novel ferrocenyl diaryl butene citrate compound as a biocide for preventing healthcare-associated infections. MEDCHEMCOMM 2016. [DOI: 10.1039/c5md00568j] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The antiseptic and disinfectant potential of a formulation containing a tamoxifen analogue was assessed according to European standards and pharmacopeia in comparison with a commercial antiseptic product.
Collapse
Affiliation(s)
- Mehdi El Arbi
- Institut Supérieur de Biotechnologie de Sfax
- Université de Sfax
- 3000 Sfax
- Tunisia
- Centre of Biotechnology of Sfax (Sfax University)
| | - Karim Jalléli
- Centre of Biotechnology of Sfax (Sfax University)
- 3018 Sfax
- Tunisia
| | - Fatma Trigui
- Centre of Biotechnology of Sfax (Sfax University)
- 3018 Sfax
- Tunisia
| | - Pascal Pigeon
- Institut Parisien de Chimie Moléculaire (IPCM) - UMR 8232
- Université Pierre et Marie Curie-Paris
- Sorbonne Universités
- 75252 Paris Cedex 05
- France
| | - Meral Görmen
- Chimie ParisTech
- Ecole Nationale Supérieure de Chimie de Paris
- Paris F75231 Paris cedex 05
- France
| | - Siden Top
- Institut Parisien de Chimie Moléculaire (IPCM) - UMR 8232
- Université Pierre et Marie Curie-Paris
- Sorbonne Universités
- 75252 Paris Cedex 05
- France
| | - Sami Aifa
- Centre of Biotechnology of Sfax (Sfax University)
- 3018 Sfax
- Tunisia
| | - Ismail Fliss
- Institute of Nutrition and Functional Foods
- Université Laval
- G1V 0A6 Québec
- Canada
| | - Gérard Jaouen
- Institut Parisien de Chimie Moléculaire (IPCM) - UMR 8232
- Université Pierre et Marie Curie-Paris
- Sorbonne Universités
- 75252 Paris Cedex 05
- France
| | - Riadh Hammami
- Institute of Nutrition and Functional Foods
- Université Laval
- G1V 0A6 Québec
- Canada
| |
Collapse
|